PDF Multi-dimensional Biomarkers and Resistance Mechanism of Targeted Therapy and Immunotherapy in Lung Cancer Download
- Author: Tao Jiang
- Publisher: Frontiers Media SA
- ISBN: 2889742652
- Category : Medical
- Languages : en
- Pages : 196
Multi-omics in studying the mechanisms of anti-cancer drugs resistance and toxicity
Immunotherapy and multimodality therapy for lung cancer
Cancer Immunotherapies: From Efficacy to Resistance Mechanisms
PDF Cancer Immunotherapies: From Efficacy to Resistance Mechanisms Download
- Author: Morten Hansen
- Publisher: Frontiers Media SA
- ISBN: 2889764419
- Category : Medical
- Languages : en
- Pages : 470
Dr. Koguchi receives funding from Tesaro, a GSK company, Bristol-Myers Squibb, and Shimadzu Corporation.. Dr. Vujanovic is a co-inventor of a methodology licensed to INmune Bio, Inc. where a selective inhibitor of soluble TNF can be used to prevent or treat malignancies. Dr. Hansen is the recipient of a private grant from Eurostars Eureka. The other Topic Editors declare no competing interests.
Towards New Promising Discoveries for Lung Cancer Patients: A Selection of Papers from the First Joint Meeting on Lung Cancer of the FHU OncoAge (Nice, France) and the MD Anderson Cancer Center (Houston, TX, USA)
PDF Towards New Promising Discoveries for Lung Cancer Patients: A Selection of Papers from the First Joint Meeting on Lung Cancer of the FHU OncoAge (Nice, France) and the MD Anderson Cancer Center (Houston, TX, USA) Download
- Author: Paul Hofman
- Publisher: MDPI
- ISBN: 3039214519
- Category : Medical
- Languages : en
- Pages : 230
This Special Issue of Cancers (Basel) is mainly dedicated to selecting papers from the talks given during the first Joint Meeting on Lung Cancer (JMLC) between the MD Anderson Cancer Center (Houston, Texas USA) and the Hospital University Federation (HUF) OncoAge (University Côte d’Azur, Nice, France) (Nice, September 2018). The central theme of JMLC is to discuss new advances and exchange ideas regarding lung cancer. Notably, the talks covered different topics on new therapeutic strategies (targeted therapy and immuno-oncology), molecular and cellular biology, biomarkers, and the epidemiology of lung cancer. Special attention was also given to lung cancer in elderly patients. The articles published in this Special Issue covered subjects such as the assessment of new biomarkers and new approaches for the early detection of lung cancer, epidemiological data, and emphasized a place for the newly characterized cellular pathways in lung cancer, which opens room for therapeutic perspectives for lung cancer patients.
Novel biomarkers for anticancer therapy
Combining chemo-radio therapy and immunotherapy for cancers—perfect mix of old and new
Updates on Combination Therapy for Lung Cancer
Tumor Microenvironment, Inflammation, and Resistance to Immunotherapies
New Therapies and Immunological Findings in Melanoma and Other Skin Cancers
PDF New Therapies and Immunological Findings in Melanoma and Other Skin Cancers Download
- Author: Atsushi Otsuka
- Publisher: Frontiers Media SA
- ISBN: 2889457125
- Category :
- Languages : en
- Pages : 137
New therapies are currently being developed in the field of skin cancer. In particular, advances in melanoma now represent the frontline of cancer immunotherapy, as immunological findings in the disease have led to the development of highly effective immune-checkpoint inhibitors. However, these immune-checkpoint inhibitors are only effective in a subset of patients, and may not work in other skin cancer types, thus highlighting the need for further innovation in the field of skin cancer treatment. The purpose of this Research Topic is therefore to provide an up-to-date overview of immune processes and new therapies for melanoma and other skin cancers in order to further stimulate the development of new and even more successful treatments.
